Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study)

Ahn Chang Ho; Han Kyung Ah; Yu Jae Myung; Nam Joo Young; Ahn Kyu Jeung; Oh Tae Keun; Lee Hyoung Woo; Lee Dae Ho; Kim Jaetaek; Chung Choon Hee; Park Tae Sun; Kim Byung Joon; Park Seok Won; Park Hyeong Kyu; Lee Kwang Jae; Kim Sang-Wook; Park Jeong Hyun; Ko Kwan Pyo; Kim Chong Hwa; Lee Hyunjin; Jang Hak Chul; Park Kyong Soo

首页> 外文期刊>Diabetes, obesity & metabolism >Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study)

【24h】

Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study)

机译：二肽素肽酶-4抑制剂的Gemiglitin的功效和安全性，2型糖尿病患者与二甲双胍和磺酰脲的组合治疗不充分控制：24周，多期，随机，双盲，安慰剂对照研究（Troica研究的）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aims: To assess the efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, added to metformin and sulphonylurea in patients with type 2 diabetes (T2DM).

机译：目的：评估Gemigliptin，二肽肽肽酶-4抑制剂的疗效和安全性，在2型糖尿病患者（T2DM）中加入二甲双胍和磺酰脲。

著录项

来源
《Diabetes, obesity & metabolism》 |2017年第5期|共9页
作者
Ahn Chang Ho; Han Kyung Ah; Yu Jae Myung; Nam Joo Young; Ahn Kyu Jeung; Oh Tae Keun; Lee Hyoung Woo; Lee Dae Ho; Kim Jaetaek; Chung Choon Hee; Park Tae Sun; Kim Byung Joon; Park Seok Won; Park Hyeong Kyu; Lee Kwang Jae; Kim Sang-Wook; Park Jeong Hyun; Ko Kwan Pyo; Kim Chong Hwa; Lee Hyunjin; Jang Hak Chul; Park Kyong Soo;
展开▼
作者单位

Seoul Natl Univ Hosp Dept Internal Med 101 Daehak Ro Seoul 03080 South Korea;

Eulji Gen Hosp Dept Internal Med Seoul South Korea;

Hallym Univ Kangnam Sacred Heart Hosp Dept Internal Med Seoul South Korea;

Ilsan Hosp Natl Hlth Insurance Serv Dept Internal Med Goyang South Korea;

Kyung Hee Univ Hosp Gangdong Dept Endocrinol &

Metab Seoul South Korea;

Chungbuk Natl Univ Hosp Dept Internal Med Cheongju South Korea;

Yeungnam Univ Med Ctr Dept Internal Med Daegu South Korea;

Wonkwang Univ Sch Med &

Hosp Dept Internal Med Iksan South Korea;

Chung Ang Univ Hosp Dept Internal Med Seoul South Korea;

Yonsei Univ Wonju Severance Christian Hosp Dept Internal Med Wonju South Korea;

Chonbuk Natl Univ Hosp Dept Internal Med Jeonju South Korea;

Gachon Univ Gil Med Ctr Dept Internal Med Incheon South Korea;

CHA Bundang Med Ctr Dept Internal Med Seongnam South Korea;

Soonchunhyang Univ Hosp Dept Internal Med Seoul South Korea;

Daedong Gen Hosp Dept Internal Med Busan South Korea;

Kangwon Natl Univ Hosp Dept Internal Med Chunchon South Korea;

Inje Univ Busan Paik Hosp Dept Internal Med Busan South Korea;

Jeju Natl Univ Hosp Dept Internal Med Jeju South Korea;

Sejong Gen Hosp Dept Internal Med Bucheon South Korea;

LG Life Sci Seoul South Korea;

Seoul Natl Univ Bundang Hosp Dept Internal Med Seongnam South Korea;

Seoul Natl Univ Hosp Dept Internal Med 101 Daehak Ro Seoul 03080 South Korea;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词
clinical trial; DPP-4 inhibitor; phase III study;

机译：临床试验;DPP-4抑制剂;第三阶段研究;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study) [J] . Ahn Chang Ho, Han Kyung Ah, Yu Jae Myung, Diabetes, obesity & metabolism . 2017,第5期

机译：二肽素肽酶-4抑制剂的Gemiglitin的功效和安全性，2型糖尿病患者与二甲双胍和磺酰脲的组合治疗不充分控制：24周，多期，随机，双盲，安慰剂对照研究（Troica研究的）
2. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial [J] . Hong S., Park C. -Y., Han K. A., Diabetes, obesity & metabolism . 2016,第5期

机译：Teneligliptin（一种新型的二肽基肽酶-4抑制剂）在韩国2型糖尿病患者中的疗效和安全性：一项为期24周的多中心，随机，双盲，安慰剂对照的III期临床试验
3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. [J] . Rosenstock J, Brazg R, Andryuk PJ, Clinical therapeutics . 2006,第10期

机译：二肽基肽酶-4抑制剂西他列汀与正在进行的吡格列酮治疗对2型糖尿病患者的疗效和安全性：一项为期24周，多中心，随机，双盲，安慰剂对照的平行组研究。
4. MULTI-CENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY OF ORAL TOCERANIB PHOSPHATE (PALLADIATM, SU11654), A RECEPTOR TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF DOGS WITH RECURRENT MAS [C] . Cheryl L London, Carolyn J Henry, Anthony W Rusk, Annual conference of the Veterinary Cancer Society . 2008

机译：多中心，安慰剂对照，双盲，随机研究口服Toceranib磷酸盐（Palladia TM，SU11654），受体酪氨酸激酶抑制剂，用于治疗经常性MAS的狗
5. Efficacy of the Chinese herbal formula CUF2 in the treatment of childhood asthma: Animal experiment, in vitro study and randomized, double-blinded, placebo-controlled clinical trial. [D] . Wong, Yeuk Oi. 2006

机译：中药配方CUF2在治疗儿童哮喘中的功效：动物实验，体外研究以及随机，双盲，安慰剂对照的临床试验。
6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter randomized open-label non-inferiority trial [O] . Hidetaka Yokoh, Kazuki Kobayashi, Yasunori Sato, 2015

机译：在单独使用二甲双胍或吡格列酮控制不充分的日本2型糖尿病患者中二肽基肽酶4抑制剂西他列汀与α-葡萄糖苷酶抑制剂相比的疗效和安全性（采用西他列汀1控制糖尿病的最终联合疗法研究）：随机开放标签非劣效性试验
7. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study [O] . M. A. Nauck, G. C. Ellis, P. R. Fleck, 2009

机译：用二甲双胍单疗法添加二肽肽酶-4型患者二肽肽酶-4抑制剂Alogliptin对二甲双胍治疗的疗效和安全性：多期，随机，双盲，安慰剂对照研究

Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study)

摘要

著录项

相似文献

相关主题

期刊订阅